Novo Nordisk's Cardiovascular Ambition Hits a Wall as ZEUS Trial Delivers a Null Result
Published on 08/01/2026 at 03:22 | Redaktion boerse-global.de
The gap between biological activity and clinical benefit has rarely been illustrated more starkly than in Novo Nordisk's latest phase-3 readout. The Danish drugmaker's experimental cardiovascular therapy Ziltivekimab did exactly what it was designed to do at the molecular level — yet failed to translate that into any meaningful improvement for patients. The market's verdict was swift and unforgiving, with the stock shedding roughly 8.6 percent on Friday to close around EUR 40.80.
A Mechanistic Success That Missed the Point
The ZEUS trial, whose results landed on 31 July 2026, enrolled more than 6,300 patients suffering from atherosclerosis, chronic kidney disease, and systemic inflammation. The study's aim was straightforward: demonstrate that Ziltivekimab could reduce major adverse cardiovascular events such as heart attacks, strokes, and cardiovascular death.
On the biomarker front, the drug delivered. It reliably suppressed inflammatory markers including hsCRP and free IL-6, confirming that the IL-6 signaling pathway was effectively blocked. But the primary endpoint told a different story. The hazard ratio came in at 0.99 — a statistical dead heat with placebo that leaves no room for interpretation. The compound reduced inflammation without reducing clinical events, a textbook illustration of why surrogate endpoints can mislead.
The Price of Diversification
The setback carries particular sting because Ziltivekimab was meant to be Novo Nordisk's ticket beyond the blockbuster weight-loss and diabetes franchise. The company acquired the asset in 2020 through its takeover of Corvidia Therapeutics, paying USD 725 million upfront. JPMorgan analysts estimate the failed program erases a revenue opportunity in the multiple billions.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Management, however, is not walking away. Martin Holst Lange, the executive responsible for research and development, has reaffirmed the company's commitment to the cardiovascular program. Two additional phase-3 trials — Hermes, examining Ziltivekimab in heart failure, and Artemis, testing it in patients following an acute myocardial infarction — remain underway, with data expected in the first half of 2027.
Financial Fallout and an Unchanged Outlook
The company has flagged a non-cash impairment charge in the third quarter of 2026 related to the failed study. Crucially, the guidance for full-year 2026 adjusted operating profit remains intact, and Novo Nordisk is pressing ahead with its share buyback program, which targets B-shares worth up to DKK 11.2 billion through February 2027.
Investors now face a short wait for the next major catalyst. Second-quarter earnings are scheduled for Wednesday, 5 August 2026, and attention will center on the commercial trajectory of the GLP-1 portfolio — particularly the rollout of oral semaglutide formulations and how the recently approved Wegovy tablet is performing in the European market following its EU authorization.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Chart Signals Point to Caution
The technical picture has deteriorated in the wake of the selloff. The shares now trade just beneath their 50-day moving average of EUR 40.90, and the distance to January's 52-week high of EUR 54.86 has widened to roughly a quarter of the stock's value. The 14-day relative strength index sits at 41.6, indicating increased selling pressure without yet reaching oversold territory.
The August earnings date now carries outsized significance. It will reveal whether the commercial engine of Ozempic and Wegovy can absorb the disappointment from the cardiovascular pipeline — and whether the market's patience with Novo Nordisk's diversification strategy has limits. For now, the Ziltivekimab program remains an open question mark, with two studies still in play and answers not expected until early 2027.
Ad
Novo Nordisk Stock: New Analysis - 1 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
